Female pattern hair loss 2026: oral minoxidil and Korean practice

Female pattern hair loss (FPHL), also known as female androgenetic alopecia, is the most common form of hair loss in women and presents quite differently from the male pattern. It produces a characteristic diffuse thinning of the central crown with preservation of the frontal hairline — a pattern often described using the Ludwig or Sinclair classifications. Despite its prevalence, FPHL has historically been undertreated, partly because the only two FDA-approved drugs for androgenetic alopecia (topical minoxidil and oral finasteride) leave compliance and efficacy gaps in many women.

The last five years have seen a meaningful practice shift, with low-dose oral minoxidil becoming a widely used off-label option, platelet-rich plasma (PRP) building an adjunctive evidence base, and Korean dermatology practices integrating these into structured combination protocols. This article summarizes what the 2020–2026 evidence supports, with attention to Korean clinical practice patterns. It is not medical advice; treatment should be planned with a board-certified dermatologist.

Mechanism: not just genes

Androgenetic alopecia results from an excessive response of genetically susceptible hair follicles to androgens, particularly dihydrotestosterone (DHT). Affected follicles undergo progressive miniaturization and a shortening of successive anagen (growth) cycles, producing thinner and shorter hairs in each cycle until the follicle becomes vellus-like or dormant [2][3]. Both inherited susceptibility and circulating androgen environment contribute, which is why diagnostic workup in women is more nuanced than in men.

Diagnostic workup

A thorough first visit for suspected FPHL includes:

• Pattern recognition: diffuse central thinning with preserved frontal hairline (Ludwig I–III or Sinclair 2–5) suggests FPHL. Patchy patterns suggest other diagnoses.
• Trichoscopy / dermatoscopy: hair shaft diameter variability, peripilar signs, and other features support the diagnosis.
• Pull test: less than five hairs per pull is consistent with stable FPHL; substantially more suggests an active shedding process such as telogen effluvium.
• Selective laboratory testing: thyroid function (TSH), serum ferritin, complete blood count, and androgen profile (testosterone, DHEAS) when clinical features suggest underlying conditions. Routine wide panels in every patient are not necessary.
• Scalp biopsy: reserved for diagnostic uncertainty or treatment failures.

Treatment categories

FDA-approved first-line

• Topical minoxidil 2% (women) or 5% (men, off-label in women): applied once or twice daily to a dry scalp. Effective in approximately half of women over 6–12 months. Compliance is the major limitation [2][3].
• Oral finasteride: FDA-approved for male pattern hair loss; off-label for women, particularly post-menopausal. Pregnancy is a strict contraindication due to teratogenicity (Category X).

Off-label but widely used

• Low-dose oral minoxidil: the most discussed practice change of the past five years. The 2020 JAAD review by Randolph and Tosti synthesized 17 studies with 634 patients and concluded that oral minoxidil is effective and well-tolerated as an alternative for patients with topical compliance issues [1]. The 2023 Drugs update reinforced this position [3]. Common adverse effects include hypertrichosis (unwanted body hair) and rare cardiovascular effects.
• Spironolactone: anti-androgen effects useful in pre-menopausal women, particularly with concomitant hormonal acne. Often combined with minoxidil.
• 5-alpha-reductase inhibitors (dutasteride): off-label, used selectively.

Adjunctive and procedural

• Platelet-rich plasma (PRP): growing evidence base for adjunctive use, particularly when combined with topical or oral therapy [2][3]. Protocols vary; typically 3 initial sessions monthly followed by maintenance every 3–6 months.
• Low-level laser therapy (LED-based devices): FDA-cleared for hair regrowth, evidence is moderate, useful as a compliance-friendly adjunct.
• Hair transplantation: appropriate for stable, late-stage cases; not first-line for early or actively progressing FPHL.
• Exosome therapies: heavily marketed in aesthetic dermatology, but the published evidence base is still limited relative to PRP. Caution about marketing claims is warranted.

Korean clinical practice patterns

Korean dermatology practices have historically been early adopters of combination protocols for FPHL. The Pan-Asian expert panel consensus published in 2021 documents the broader Asian dermatologic approach to aesthetic and restoration combinations [4]. In Korean clinical practice specifically, several Seoul-based dermatology practices — including Delight Dermatology Clinic in Gangnam, Apgujeong Oracle Dermatology Center, Leaders Dermatology Clinic, and others — have described structured combination protocols that integrate:

• Topical minoxidil 5% or low-dose oral minoxidil as the systemic anchor.
• PRP as the procedural adjunct, typically 3 initial sessions followed by maintenance.
• Spironolactone in pre-menopausal patients with concurrent hormonal indications.
• Trichoscopic monitoring at each visit for hair shaft diameter and peripilar signs.

Disclosure: Dr. SangYoul Yun, who medically reviews DermatologyNews articles, practices at Delight Dermatology Clinic. We have referenced multiple Seoul practices to provide balanced clinical context, and the editorial selection reflects publicly documented practice patterns rather than promotional intent.

What does not have strong evidence

• Megadose biotin supplementation in patients with normal levels — not consistently supported by evidence and can interfere with laboratory thyroid tests.
• Caffeine shampoos and most over-the-counter "hair growth" cosmetics — minimal rigorous evidence beyond very small studies.
• Stem cell injection products marketed for hair loss — the evidence base does not yet support routine use; risk-benefit and regulatory status vary by country.

Counseling and realistic expectations

• FPHL is chronic. Treatments slow miniaturization and may partially reverse it, but treatment is typically lifelong to maintain effect.
• Initial shedding phase in the first 8 to 12 weeks of starting topical or oral minoxidil is part of the synchronization of the hair cycle, not treatment failure.
• Photographic monitoring at 3, 6, and 12 months is the most reliable assessment, more than subjective impression.
• Psychological impact is substantial; some patients benefit from counseling support alongside medical therapy.

Bottom line

Female pattern hair loss benefits from a structured diagnostic and multimodal treatment approach. Low-dose oral minoxidil has become a widely used off-label option for patients who struggle with topical compliance, and Korean dermatology practices have integrated this into combination protocols with PRP and selectively used anti-androgens [1][3][4]. Realistic counseling about chronicity, initial shedding phase, and lifelong maintenance is part of responsible management.

This article is for informational purposes and does not constitute medical advice.